There are signs that it may be related to abnormal blood clots
British authorities on Wednesday advised against vaccinating AstraZeneca’s COVID-19 vaccine for adults under 30 years of age because there is increasing evidence that the vaccine may be related to abnormal blood clots.
Regulators in the United Kingdom and the European Union pointed out that although the benefits to most people outweigh the risks to most people, the European Medicines Agency (EMA) said it has found a “possible link” between the vaccine and blood clots. The British authorities recommend alternatives for people under 30, but the EMA did not make recommendations based on age, instead handing over the decision to its member states.
Belgium also ignored EMA’s recommendations and imposed a four-week AstraZeneca vaccine ban on people under 56 years of age.
Belgian Health Minister Frank Vandenbroucke said: “We will keep it for four weeks, and then we will re-evaluate it.” He added that this decision will hardly affect the campaign, because People of this age rarely get vaccinated this month.
Several countries/regions restrict who can get the vaccine, and attention to these measures is high because the AstraZeneca vaccine is cheaper than many other countries, easier to store, is essential for the global immunization campaign, and is COVAX Pillars. Supported programs to bring vaccines to the poorest countries.
Jonathan Van-Tam, England’s second medical officer, said at a press conference: “There is no doubt that this is a revision of a course.” “But in a sense, over time. Over time, it is medically normal for doctors to change their preferences for treating patients.”
Van Tam said the impact on the British vaccination campaign (one of the fastest vaccines in the world) will be “zero or negligible”, provided that the NHS receives the expected doses of Pfizer, Moderna and Pfizer vaccines from other pharmaceutical companies. .